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To determine whether particular environmental, medi-
cal, or behavioral risk factors existed among Cryptcoccus 
gattii–infected persons compared with the general popula-
tion, we conducted a sex-matched case−control study on 
a subset of case-patients in British Columbia (1999–2001). 
Exposures and underlying medical conditions among all 
case-patients (1999–2007) were also compared with re-
sults of provincial population–based surveys and studies. 
In case−control analyses, oral steroids (matched odds ra-
tio [MOR] 8.11, 95% conﬁ  dence interval [CI] 1.74–37.80), 
pneumonia (MOR 2.71, 95% CI 1.05–6.98), and other lung 
conditions (MOR 3.21, 95% CI 1.08–9.52) were associated 
with infection. In population comparisons, case-patients 
were more likely to be >50 years of age (p<0.001), current 
smokers (p<0.001), infected with HIV (p<0.001), or have 
a history of invasive cancer (p<0.001). Although C. gat-
tii is commonly believed to infect persons with apparently 
healthy immune systems, several immunosuppressive and 
pulmonary conditions seem to be risk factors.
C
ryptococcus gattii emerged on Vancouver Island, 
British Columbia (BC), Canada, in 1999, resulting in 
one of the highest incidences of this infection worldwide 
(1,2). The natural reservoir of C. gattii seems to be soil 
and plant debris, and it has been associated with numer-
ous tree species (3,4). When inhaled, this encapsulated ba-
sidiomycetous yeast may infect humans as well as diverse 
animal species (5). Infected humans may be asymptomatic 
but usually exhibit pulmonary infection characterized by 
cough, shortness of breath, and single or multiple pulmo-
nary nodules visible on radiographs of the lung. Body sites 
such as brain, skin, and bone are affected less commonly 
(6,7). Approximately 18% of patients in British Columbia 
have disseminated disease, including meningitis and brain 
cryptococcomas (1). The case-fatality rate among BC resi-
dents during 1999–2007 was 8.7% (1).
C. gattii is believed to infect persons with uncompro-
mised immune systems (8,9), unlike C. neoformans, a rela-
tively common opportunistic pathogen in HIV-infected pa-
tients and other immunocompromised patients. Although 
true differences in species-speciﬁ  c pathogenicity may ex-
ist, C. gattii may also commonly infect persons with unde-
tected immune deﬁ  ciencies. Early studies have identiﬁ  ed 
several risk factors for Cryptococcus spp. infection; how-
ever, these do not distinguish between species. In experi-
mental studies, steroids have been shown to decrease host 
resistance to infection (10). Case-series investigations have 
linked corticosteroid use with an increased risk of dying 
from cryptococcal meningitis (11) and with an increased 
risk for disseminated disease (12). A nationwide survey of 
163 HIV-negative cryptococcosis patients in France (1985–
1993) showed that having malignancies (32%), undergoing 
organ transplantation (19%), and receiving corticosteroid 
therapy (33%) were the main predisposing factors (13). 
Other frequently identiﬁ   ed predisposing conditions for 
cryptococcosis include sarcoidosis, hyper-immunoglobulin 
(Ig) M and hyper–IgE syndromes, and CD4+ T-cell lym-
phopenia in those who are HIV negative (14). Case reports 
have also suggested that cirrhosis is a risk factor for crypto-
coccal peritonitis (15).
Cryptococcal infections are rare in children, no mat-
ter their HIV status (16). Historical studies of cryptococ-
cosis patients have shown that higher proportions of male 
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patients had the disease, both before and after the HIV 
epidemic (14). The risk for disseminated infection among 
HIV-positive persons with cryptococcal infection was al-
most 4× higher for those who smoked at the time of diag-
nosis than for those who did not (17).
Many studies that examined predisposing factors for 
Cryptococcus infection in humans have done so in select-
ed populations (e.g., HIV-positive patients), and assess-
ment has been frequently limited to medical rather than 
behavioral or environmental exposures. Often laboratory 
testing was not undertaken to distinguish patients with C. 
gattii infection from those with C. neoformans infection. 
In newer studies, which have obtained subtyping informa-
tion, typically, the number of C. gattii isolates was insuf-
ﬁ  cient to determine risk factors. Risk factors suggested in 
the medical literature have arisen from case reports and 
case series that described the proportion of patients with 
particular underlying conditions. Although some investi-
gations have compared risk factors between patients with 
C. gattii and those with C. neoformans infections (8,9), 
we could ﬁ  nd no examples in which case-patients were 
compared with healthy controls to determine risks for 
disease acquisition.
Ecologically, epidemiologically, and clinically, C. gattii 
is sufﬁ  ciently different from its fungal relative C. neoformans 
(including C. neoformans var. grubii and C. neoformans var. 
neoformans) to warrant its own species designation (18). It 
therefore seems reasonable to assume that the risk factors for 
disease acquisition may not be the same. We undertook this 
current investigation to determine whether, compared with 
the general population, particular medical, behavioral, or en-
vironmental risk factors existed among case-patients with C. 
gattii infection in British Columbia, Canada.
Methods
Risk factors for C. gattii infection were evaluated in 2 
ways. First, a case–control study was conducted on a sub-
set of case-patients (1999–2001) to examine which medical 
and environmental exposures increased the odds of infec-
tion. Second, risk behaviors and underlying medical condi-
tions of all case-patients (1999–2007) were compared with 
those of the general BC population by using existing data 
from population-based surveys and studies.
Case Ascertainment
Patients who became study participants included 
those with culture-conﬁ  rmed C. gattii infection (for which 
genotyping had been done) as well as those with labora-
tory evidence of cryptococcal infection (determined from 
antigen detection and histopathologic or microscopic ex-
amination) who were also HIV negative and had been ex-
posed to a local C. gattii–endemic area in the year before 
disease onset (1,2). HIV status and geographic exposure 
were included as part of the case deﬁ  nition for patients 
from whom culture results were unavailable because hos-
pitalization rates had increased sharply in this population 
group in 1999, signaling the onset of the C. gattii outbreak 
in British Columbia (2). Information on case-patients was 
obtained from the BC Cryptococcus Database, which con-
tains laboratory and interview data from patients with a di-
agnosis since 2001 when infection with Cryptococcus spe-
cies became reportable. All available isolates are routinely 
sent to the British Columbia Centre for Disease Control 
Public Health Microbiology and Reference Laboratory for 
culturing, serotyping, and molecular characterization. Cas-
es diagnosed before 2001 were identiﬁ  ed either through 
reporting by laboratory physicians or through a review of 
the Provincial Electronic Hospital Separation Database for 
the years 1995–2001 for records containing the Interna-
tional Classiﬁ  cation of Diseases, 9th Revision (ICD-9), 
code 117.5 (cryptococcosis) without ICD-9 codes V08 
and 042.X (HIV/AIDS). Stored clinical isolates were also 
typed retrospectively (2). Specimens were identiﬁ  ed as 
C. gattii as previously described (19–21).
Case−Control Study
Thirty-eight BC residents whose C. gattii infections 
were diagnosed from January 1999 through December 
2001 were eligible for inclusion in the case–control study. 
Two controls per case-patient were identiﬁ  ed through the 
general practitioners of the infected persons. Controls were 
matched with case-patients by sex since this was consid-
ered a likely confounder for many behavioral risk factors. 
Controls were required to have had a chest radiograph 
showing absence of active pulmonary disease after their 
matched case-patient’s date of diagnosis.
Case-patients and controls were interviewed twice by 
using structured, in-depth questionnaires. The ﬁ  rst inter-
view was conducted face to face at the participants’ homes. 
Information collected included demographic variables; 
medical history (e.g., has a doctor ever diagnosed you with 
X?), smoking status; clinical symptoms; occupation; travel 
history; recreational activities; gardening and landscaping 
activities; construction activities; and exposure to botanical 
gardens, zoos, aquariums, agriculture, animals, compost, 
bark mulch, various tree species, and wooded areas. Case-
patients were asked to consider activities in the 3 months 
before onset of symptoms. Controls were interviewed about 
the exposure period corresponding to their matched case-
patient. Current smokers were those who self-identiﬁ  ed 
as smokers of cigarettes or cigars at the time of interview. 
Respondents who had ever smoked were persons who had 
smoked cigarettes or cigars on a regular basis at some point 
in their lives.
Frequency analysis was performed by using SPSS 
version 10.0 (SPSS Inc, Chicago, IL, USA). Matched 
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odds ratios and 95% conﬁ  dence intervals were calculated 
by using S-Plus version 6.0 (MathSoft Inc, Seattle, WA, 
USA). Stratiﬁ  ed analyses were conducted to explore poten-
tial confounding relationships. Logistic regression was not 
possible because of the collinearity of the data and small 
sample size.
Population Comparison
Information on a smaller number of risk factors (than 
obtained from the questionnaire) was also routinely col-
lected from case-patients, their physicians, or both, dur-
ing standardized public health interviews of all BC case-
patients from 1999 through 2007. Data were collected from 
symptomatic and asymptomatic case-patients. Past medical 
conditions were included; steroid use was evaluated over 
the 3-month period before onset of infection for case-pa-
tients whose conditions were diagnosed during 1999–2001 
and over a 12-month period for later identiﬁ  ed case-pa-
tients. The proportion of C. gattii–infected case-patients 
was calculated for the following age groups: 0–19 20–39, 
40–49, 50–59, 60–69, 70–79, and >80 years. Proportions 
were also tabulated of case-patients who were male, were 
current smokers at the time of interview, were infected with 
HIV, had chronic obstructive pulmonary disease (COPD) 
or asthma, had taken systemic corticosteroids, or had a 
history of invasive cancer. Invasive cancer included all 
cancers reported, including melanoma (but no other skin 
cancers). Prevalence proportions were calculated among 
case-patients for whom data on a particular risk factor 
were available. Prevalence proportions for C. gattii case-
patients were then compared with prevalence proportions 
for the general BC population obtained from existing data 
sources. These included provincial statistics on age and sex 
distribution (22), BC smoking prevalence estimates from a 
national community health survey (23), and type-speciﬁ  c 
cancer prevalence from the BC Cancer Agency (24). Pro-
vincial estimates of HIV prevalence, derived by previously 
published methods (25), were provided by BC Centre for 
Disease Control (M. Gilbert, pers. comm.). We used the 
χ2 test for small dependent populations in Microsoft Excel 
(Microsoft Corp., Redmond, WA, USA) to compare preva-
lence of risk factors among C. gattii case-patients with the 
overall BC population. 
Results
Case–Control Study
During 1999–2001, 38 case-patients met the case 
deﬁ  nition criteria for inclusion in the case–control study. 
Nineteen cases were diagnosed by culture, the remaining 
19 by histopathologic examination. Isolates from 18 case-
patients with culture-conﬁ  rmed infection were C. gattii, 
serotype B; 1 isolate could not be retrieved for subtyping. 
None of the 38 patients was HIV positive. The mean age at 
diagnosis was 59.7 years (range 20–82 years; SD 13.49); 
22 were male. Thirty-six case-patients were Caucasian, and 
2 were of Asian descent, which is consistent with provin-
cial ethnicity statistics (data not shown). Thirty were retired 
or unemployed at the time of their illness. Ten case-patients 
had cryptococcal meningitis when they sought treatment; 
the remainder exhibited respiratory infection. The most 
common self-reported symptoms were cough (21 patients), 
shortness of breath (20 patients), night sweats (20 patients), 
and fever (20 patients).
Thirty matched sets of case-patients and controls were 
interviewed (8 case-patients could not be matched). No sig-
niﬁ  cant difference in age was found (p = 0.24). Case-pa-
tients were more likely than controls to report having ever 
received a physician’s diagnosis of pneumonia (matched 
odds ratio [MOR] 2.71, 95% conﬁ  dence interval [CI] 1.05–
6.98) or other lung conditions (MOR 3.21, 95% CI 1.08–
9.52) (Table 1). Case-patients were also more likely than 
controls to have taken systemic corticosteroids (MOR 8.11, 
95% CI 1.74–37.80), including prednisone (12 case-pa-
tients) and methylprednisolone (1 case-patient), during the 
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Table 1. ORs for risk factors for Cryptococcus gattii infection for 
30 matched case-patient and general population sets, British 
Columbia, Canada, 1999–2007* 
Risk factors  MOR (95% CI) 
Medical  
 Lung  conditions†  3.21 (1.08–9.52) 
 Pneumonia  2.71 (1.05–6.98) 
 Asthma  0.45  (0.12–1.66) 
 Diabetes  0.65  (0.17–2.50) 
 Anemia  2.64  (0.74–9.44) 
 Arthritis  0.97  (0.37–2.49) 
  Liver disease  4.00 (0.36–44.10) 
 Cancer  2.03  (0.63–6.81) 
  Other fungal infections  1.69 (0.23–12.20) 
 Tuberculosis  3.24  (0.29–36.60) 
 Oral  steroid  use‡  8.11 (1.74–37.80) 
  Current smoker  1.00 (0.34–2.93) 
  Ever smoked  1.18 (0.44–3.20) 
Environmental‡§  
  Living with 1 mile of woods   1.70 (0.17–2.02) 
  Outdoor building or repairing house  4.00 (1.00–16.00) 
 Cutting/chopping  wood  0.17 (0.04–0.76) 
 Pruning  0.28 (0.09–0.88) 
  Cleaning up branches   0.29 (0.10–0.84) 
  Digging earth  0.93 (0.38–2.30) 
 Camping  1.23  (0.23–2.91) 
 Gardening  1.15  (0.47–2.79) 
*MOR, matched odds ratio; CI, confidence interval. Boldface indicates 
significant risk factors. 
†Includes emphysema, chronic bronchitis, chronic obstructive pulmonary 
disease, sarcoidosis. 
‡In 3 mo before symptom onset. 
§Other environmental risk factors not significant at Į = 0.05: animal or crop 
farm within 1 mile of residence; construction or landscaping activities; 
cleaning of buildings, eaves, troughs, or bird feeders; contact with 
individual tree species; visits to botanical gardens; boating; use of compost 
materials and bark mulch. RESEARCH
3 months before their illness. No single indication for ste-
roid therapy predominated among case-patients. Although 
oral steroid use had the strongest association with C. gattii 
infection, stratiﬁ  ed analysis did not identify confounding 
effects on other variables. Neither smoking nor a history of 
cancer was associated with illness. Chopping wood, prun-
ing trees, and cleaning up branches were signiﬁ  cantly less 
commonly reported among case-patients than among con-
trols, whereas 1 activity, conducting outdoor repairs to a 
house or building, was more common among case-patients.
Population Comparison
Among 218 C. gattii case-patients reported in British 
Columbia from 1999–2007, 124 (56.9%) had a culture-
conﬁ   rmed infection. The mean age was 58.7 years. Of 
case-patients with risk factor information available, 65 
(41.9%) of those >12 years of age smoked at the time of di-
agnosis, 6 (3.7%) had HIV infection, and 38 (24.7%) had a 
history of invasive cancer. The most common forms of can-
cer reported were leukemia (n = 7), lymphoma (n = 6), and 
lung (n = 6). Seventy (38.0%) case-patients who provided 
information were considered to be immunocompromised 
(i.e., had an HIV infection, an organ transplant, a history of 
invasive cancer, and/or used systemic corticosteroids in the 
year before diagnosis).
Those with C. gattii infection were more likely than 
the general population to be >50 years of age (p<0.001), 
be current smokers (p<0.001), be infected with HIV 
(p<0.001), or have a history of invasive cancer (p<0.001) 
(Table 2). C. gattii–infected persons were more likely 
than the general population to belong to age groups >50 
years (i.e., 50–59 years, 60–69 years 70–79 years, and >80 
years). The incidence of C. gattii infection was highest in 
those 70–79 years of age (2.5/100,000 population). Male 
sex was not associated with infection (p = 0.198) (Table 2). 
Those with C. gattii infection were not more likely to have 
a history of COPD or asthma than were the general popula-
tion. Although 30 (27.0%) of 111 patients with available 
information had used systemic steroids in the 12 months 
before diagnosis, no valid population controls were found 
for comparison.
Discussion
This controlled study identiﬁ  es demographic, medical, 
and behavioral risk factors for C. gattii acquisition. No-
tably, ≈40% of C. gattii–infected patients were immuno-
compromised. This represents a departure from the preva-
lent view that C. gattii infects otherwise healthy persons. 
However, the proportion of immunocompromised patients 
remains lower than estimates of immunocompromise for 
patients infected by C. neoformans, many of whom have 
severe immunologic disorders (26).
In contrast to previously reported ﬁ  ndings of an associ-
ation between cryptococcal species infection and male sex, 
even when adjusting for HIV status (14), C. gattii patients 
in British Columbia were not statistically more likely to 
be male. It has been hypothesized that sex differences may 
be the result of differential environmental exposure during 
occupational or leisure activities. In British Columbia, sex 
differences are unlikely, given the widespread detection of 
the fungus in the environment, including urban and semi-
urban settings. Previous studies that have demonstrated sex 
differences were not species speciﬁ  c and likely included 
a disproportionate number of persons with C. neoformans 
infection; thus, gender may not inﬂ  uence acquisition of C. 
gattii speciﬁ  cally.
C. gattii patients in British Columbia were more likely 
than the provincial population to be >50 years of age. The 
relative absence of pediatric case-patients (4 patients in 
9 years) conﬁ  rms reports in other jurisdictions (16). This 
ﬁ  nding may have resulted from differential exposure, as 
suggested by serosurveys in Australia (16). In a New York 
study, however, most children had acquired antibodies to 
C. neoformans by the age of 5 years (27). Alternately, ad-
vancing age may be a risk factor simply because older per-
sons are more likely to have medical risk factors for C. gat-
tii infection or have had their immune function decline with 
age. In the case–control analysis, no signiﬁ  cant difference 
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Table 2. Comparison of risk factor prevalence among Cryptococcus gattii–infected patients and the general population, British 
Columbia, Canada, 1999–2007 
Risk factor 
Prevalence, % (95% confidence interval) 
p value  C. gattii–infected case-patients  General population 
Age >50 y  72.4 (64.9–79.8)  31.3 <0.001 
Male sex  55.8 (46.4–65.1)  49.6 0.198 
Current smoker  41.9 (35.3–48.6)  17.8 (16.9–18.6)*  <0.001 
All invasive cancers  24.7 (21.7–27.7)  3.6 <0.001 
  Leukemia/lymphoma only  8.4 (7.6–9.2)  0.3 <0.001 
  Lung only  3.9 (3.3–4.5)  0.1 <0.001 
HIV infection  3.7 (2.9–4.4)  0.2 <0.001 
Chronic obstructive pulmonary disease  4.1 (0.5 to 9.6)  8.0† 0.090 
Asthma 3.4 (1.1 to 7.9)  7.8 0.054 
*From original data source. 
†Estimated based on range provided.  Risk Factors for Cryptococcus gattii Infection
in age was detected between case-patients and controls; 
therefore, this relationship could not be studied. The lack 
of age association between case-patients and controls may 
have been because of bias toward the inclusion of older 
controls because they were selected on the basis of a recent 
chest radiograph showing no abnormalities—a procedure 
more likely to be routinely performed in older patients.
In the case–control study, C. gattii–infected case-
patients were signiﬁ   cantly more likely than controls to 
have received systemic corticosteroid therapy. Increased 
susceptibility to cryptococcal infection after corticosteroid 
therapy has previously been described (28). Mouse experi-
ments by Levine et al. in the 1950s demonstrated that mice, 
which usually were able to localize an induced subcuta-
neous cryptococcocal infection, could not do so after an 
intraperitoneal injection of 2.5 mg of cortisone acetate (10). 
Among US patients with culture-conﬁ  rmed cryptococcal 
meningitis, persons who had received >20 mg of predni-
sone or who had Hodgkin lymphoma or other lymphoretic-
ular malignancies were at signiﬁ  cantly higher risk of dying 
than those without these conditions (11). In another case 
series of Cryptococcus-infected patients, disseminated dis-
ease developed in 59% of those treated with corticosteroids 
(12). More recently, corticosteroid use has been identiﬁ  ed 
as a risk factor for disseminated disease in HIV-negative 
patients with pulmonary cryptococosis (29). Because oral 
steroids are sometimes used to treat cryptococcal infec-
tions, these ﬁ  ndings present a medical challenge.
In the case–control study, a history of pneumonia 
or other lung conditions (including emphysema, chronic 
bronchitis, COPD, sarcoidosis) was associated with cryp-
tococcosis. Pneumonia alone may not be an independently 
associated risk factor because it is associated with many 
lung conditions. Certain respiratory conditions, including 
bronchial obstruction, predispose the patient to recurrent 
bacterial pneumonia (30,31), and bronchopulmonary disor-
ders may predispose a person to pulmonary cryptococcosis 
(32) because airway damage leads to a decreased barrier 
to infection. C. gattii–infected case-patients were not more 
likely than population controls to have experienced COPD, 
when that factor was examined alone. Notably, asthma was 
not identiﬁ  ed as a risk factor by either the case–control or 
population-level analyses, although this condition, along 
with COPD, has been suggested as a risk factor (31).
Invasive cancers of all types were signiﬁ  cantly more 
common in C. gattii–infected patients than in the general 
population. This ﬁ  nding held true for subgroups of patients 
with lung cancer and leukemia/lymphoma. Lymphoprolif-
erative malignancies have traditionally been considered 
risk factors for cryptococcal infection and disseminated 
disease (14), and this appears to remain true for C. gattii–
infected populations speciﬁ  cally. Although invasive can-
cers likely lead to an increased risk for infection, C. gattii 
infection may have been an incidental ﬁ  nding in patients 
with lung cancer, with the detection of the former facili-
tated through imaging and invasive procedures used for di-
agnosing the latter. In the case–control study, MORs also 
suggested that odds of infection were elevated for those 
with a history of invasive cancers; however, this difference 
was not signiﬁ  cant.
During 1999–2007, six cases of culture-conﬁ  rmed C. 
gattii infections were documented in HIV-positive resi-
dents of British Columbia. Although such cases are rec-
ognized (33,34), HIV infection has generally been associ-
ated with C. neoformans infection. This study highlights 
that HIV infection, although rare in C. gattii patients, is 
signiﬁ  cantly more likely to be found in this patient group 
than in the general population. In fact, the strength of this 
relationship may have been underestimated: since HIV-
positive persons with cryptococcal infection of undeter-
mined species were excluded from the case deﬁ  nition, 
some  C. gattii infections among HIV-positive patients 
may have been missed. Although the speciﬁ  c reason is 
unknown, HIV status may be associated with C. gattii in-
fection because of differences in strain pathogenicity and 
host immune response.
Three outdoor activities—chopping wood, pruning, 
and cleaning up branches—were protective against infec-
tion. The reason for this is not clear because these activities 
would potentially have exposed the person to C. gattii in 
trees. Ongoing low-level exposure possibly results in im-
munity, preventing symptomatic infection if the person is 
exposed to a higher dose. More likely, these more vigorous 
activities are undertaken by healthy persons and reﬂ  ect a 
general state of wellness rather than a protective effect of 
these speciﬁ  c behaviors. In contrast, outdoor building re-
pairs represented a risk factor for infection. This may have 
been due to the disturbance of rotting wood colonized with 
C. gattii. Environmental experiments in British Columbia 
have demonstrated substantially increased airborne con-
centrations of C. gattii when colonized trees are felled or 
chipped (35). 
Population comparisons suggest that signiﬁ  cantly 
more C. gattii–infected case-patients are current smokers. 
Because smoking compromises the protective barriers in 
airways, it has been linked to increased risk for many lung 
infections (36). A previous study of AIDS patients with C. 
neoformans infection, which identiﬁ  ed smoking as a risk 
factor for disseminated disease, suggested that fungus may 
be inhaled along with smoke particulates and deposited 
in small airways (17). Air-sampling studies of C. gattii in 
British Columbia have found that the airborne propagule 
is sufﬁ  ciently small to be deposited in the upper lung (i.e., 
from 3.3 μm to >7 μm (37).
This study has several limitations. First, to ensure that 
asymptomatic C. gattii–infected patients were not included 
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as controls, we required controls to have had chest radio-
graphs showing no abnormalities. A selection bias may 
have been introduced, which could have reduced the likeli-
hood of showing signiﬁ  cant differences among variables, 
such as smoking, that might be associated with having a ra-
diograph taken, leading to more conservative estimates or 
an inability to detect true differences in exposures between 
case-patients and controls. Similarly, the small sample size 
of the case–control study may have limited its power to 
detect signiﬁ   cant exposures. Therefore, when possible, 
population comparisons were also performed to validate 
case–control ﬁ  ndings.
In addition, risk factors for both analyses were col-
lected by self-report, which may have been inaccurate. 
Also, the case–control analysis examined risk factor in-
formation in the 3 months before disease onset. Subse-
quent research has shown that the incubation period for 
this disease is typically longer (38). This long incubation 
period may have affected the study’s ability to accurately 
detect behavioral and environmental risk factors; medi-
cal risk factors were unaffected because these were re-
ported as “ever diagnosed with.” Despite a case deﬁ  nition 
speciﬁ   cally designed to exclude case-patients infected 
with C. neoformans, some misclassiﬁ  cation may have oc-
curred, given that only 50% of infections in case-patients 
included in the case–control study and 57% of infections 
in case-patients included in population comparisons could 
be conﬁ  rmed by laboratory typing.
Conclusion
Although most cases of C. gattii infection do occur in 
otherwise healthy persons, our ﬁ  ndings suggest that infec-
tion is associated with immunosuppressive states induced 
by oral corticosteroid use and invasive cancers as well as 
with weakened pulmonary function resulting from previ-
ous lung infections and smoking (Table 3). Despite HIV 
infection being rare among C. gattii–infected case-patients, 
it also occurred more frequently in infected persons than 
in the general population. Recent evidence indicates that 
C. gattii is now spreading in the Paciﬁ  c Northwest of the 
United States (19,39). Physician awareness of risk factors 
should assist with diagnosis of this serious but treatable in-
fection in areas where the disease is emerging.
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